

Anti-TIM-3/KIM-3/HAVCR2 Antibody-HRP (8Q22)

Product Details

| | |
|---------------|-------------|
| Ig Type: | Mouse IgG2b |
| Reactivity: | Human |
| Conjugation: | HRP |
| Clone: | 8Q22 |
| Purification: | Protein A |

Applications

| | |
|--------------|--------------------|
| Application: | ELISA |
| Recommended | ELISA: 0.1-1 µg/ml |

Properties

| | |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Stability & Storage: | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. Keep away from direct sunlight. |
| Shipping: | Shipping with blue ice. |

Antigen Details

| | |
|------------------|------------------------------------------------------------------------------------------|
| Immunogen: | Recombinant Protein: Human TIMD3 protein (TMPY-01621) |
| Antigen Species: | Human |
| Synonyms: | TIMD3;HAVCR2;TIM3;TIMD-3;Tim-3;CD366;HAVCR-2;hepatitis A virus cellular receptor 2;KIM-3 |
| Biology Area: | Cancer Drug Targets |

Research Background

Hepatitis A virus cellular receptor 2 (HAVCR2), formerly known as T cell immunoglobulin and mucin domain-3 (TIM-3), is a transmembrane glycoprotein expressed on the surface of terminally differentiated Th1 cells but not on Th2 cells. It was the first surface molecule that specifically identifies Th1 cells in both the mouse and human. Recently, the identification of Galectin-9 as a ligand for TIM-3 has established the TIM-3-Galectin-9 pathway as an important regulator of Th1 immunity and tolerance induction. Engagement of Tim-3 by its ligand galectin-9 negatively regulates IFN-gamma secretion and influences the ability to induce T cell tolerance in both mice and man. It suggests a novel paradigm in which dysregulation of the TIM-3-galectin-9 pathway could underlie chronic autoimmune disease states, such as multiple sclerosis. Recent work has explored the role of TIM-3 in systemic lupus erythematosus (SLE), and their results indicate that TIM-3 may represent a novel target for the treatment of SLE. Numerous studies have demonstrated that Tim-3 influences autoimmune diseases, including diabetes and multiple sclerosis, and its role in other inflammatory diseases including allergies and cancer is beginning to become clear. In the tumor rejection model, the soluble form of Tim-3 (sTim-3) significantly impaired T cell antitumor immunity, evidenced by decreased antitumor CTL activity and reduced amount of tumor-infiltrating lymphocytes in the tumor. sTim-3 as an immunoregulatory molecule that may be involved in the negative regulation of T cell-mediated immune response. Cancer Immunotherapy Co-inhibitory Immune Checkpoint Targets Immune Checkpoint Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: IP Antibodies Immune Checkpoint Detection: WB Antibodies Immune Checkpoint Proteins Immune Checkpoint Targets Immunotherapy Targeted Therapy

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481